Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2005
12/06/2005US6972295 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis
12/06/2005US6972171 mixing polynucleotides with folic acid, hormones, peptides, glycoproteins, lipids or phosphatides to form nucleotides used as drugs; genetic engineering; gene expression
12/06/2005US6972168 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture
12/06/2005US6972127 administering an effective dose of a polypeptide comprising an immunogenic fragment of A beta (SEQ ID NO:1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the A beta fragment; Alzheimer's disease
12/06/2005CA2362834C Modulators of beta-amyloid peptide aggregation comprising d-amino acids
12/06/2005CA2354606C Azabicycloalkane derivatives and therapeutic uses thereof
12/06/2005CA2352528C Phosphatidyl-l-serine and phosphatidic acid composition as anti-depressant, stress suppressor and mood improver
12/06/2005CA2347512C Adenine derivatives
12/06/2005CA2303244C Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
12/06/2005CA2289599C Substituted heterocyclic compounds, method for preparing and compositions containing same
12/06/2005CA2268866C Substituted arylalkylamines as neurokinin antagonists
12/06/2005CA2173257C Novel (r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benzopyranes
12/06/2005CA2148593C Use of piperazine derivatives for the treatment of cognitive disorders
12/06/2005CA2129527C Pharmaceutical composition usable as an analgesic, comprising (r)-(benzoyl-3-phenyl)-2-propionic acid
12/06/2005CA2095708C Novel n-aralkyl- and n-heteroaralkyl-aminoalkanephosphinic acids
12/03/2005CA2529613A1 Agent for repairing corneal sensitivity containing amide compound
12/01/2005WO2005113586A2 Disease-associated proteins
12/01/2005WO2005113541A1 Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
12/01/2005WO2005113517A1 Phosphodiesterase-inhibiting compounds of the 2,3-benzodiazepine type
12/01/2005WO2005113501A1 Neurogenic pain control agent composition
12/01/2005WO2005113014A1 siRNA TO VP-1 OF JC VIRUS AND MEDICINAL COMPOSITION CONTAINING THE SAME
12/01/2005WO2005113002A1 Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
12/01/2005WO2005112972A1 Methods of treating disease with random copolymers
12/01/2005WO2005025487A3 Oligonucleotides targeting prion diseases
12/01/2005US20050267212 Omega-3 fatty acids in the treatment of depression
12/01/2005US20050267205 2,4-dihydroxybenzoic acid derivatives
12/01/2005US20050267203 Carbamate compounds for use in preventing or treating anxiety disorders
12/01/2005US20050267196 Reducing tumor necrosis factor; phosphodiesterase inhibitor; anticancer agents; antidepressants; antiinflammatory agents; skin dsorders; antidepressants
12/01/2005US20050267190 Solid-state form of celecoxib having enhanced bioavailability
12/01/2005US20050267189 Celecoxib compositions
12/01/2005US20050267186 Minimal cardivascular and/or sedatory activity; treating pain and allodynia; selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors;
12/01/2005US20050267183 Selective estrogen receptor modulators
12/01/2005US20050267168 Pentanoic acid derivatives
12/01/2005US20050267167 Pentanoic acid derivatives
12/01/2005US20050267165 Il-8 receptor antagonists
12/01/2005US20050267163 Vanilloid receptor ligands and their use in treatments
12/01/2005US20050267155 Constrained himbacine analogs as thrombin receptor antagonists
12/01/2005US20050267152 Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
12/01/2005US20050267147 Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament
12/01/2005US20050267133 Pyrazolopyrimidines as kinase inhibitors
12/01/2005US20050267126 Compounds derived from aryl carbamates, preparation thereof and uses of same
12/01/2005US20050267122 Ansamycins having improved pharmacological and biological properties
12/01/2005US20050267121 Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant
12/01/2005US20050267114 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
12/01/2005US20050267112 intravenous or oral administration; hypotensive agents; enzyme inhibitors of cGMP-metabolizing phosphodiesterases
12/01/2005US20050267111 Pharmaceutical compositions and methods for use
12/01/2005US20050267107 4-alkyl-/4-alkenyl-/4-alkynyl methyl/-1-aryl-cyclohexylamine compounds
12/01/2005US20050267029 Compounds which modulate amyloidogenesis and methods for their identification and use
12/01/2005US20050266533 Therapeutic fusion protein with enhanced for use in prevention and treatment of cell proliferative, blood and nervous system disorders
12/01/2005US20050266532 Albumin fusion proteins
12/01/2005US20050266502 Methods, compositions and compound assays for inhibiting amyloid-beta protein production
12/01/2005US20050266501 Reagent for detecting risk factor of alzheimer's disease, detection kit therefor and method of detecting risk factor of alzheimer's disease using the same
12/01/2005US20050266485 polynucleotides encoding a hematopoietic cytokine receptor polypeptide, for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs; test detecting a genetic disorder, cancer
12/01/2005US20050266108 Methods of purifying cannabinoids from plant material
12/01/2005US20050266060 Transdermal delivery system for treatment of cognitive disorders
12/01/2005US20050266029 with botulinum toxin
12/01/2005US20050266002 Methods for the treatment of cancer using anti-CD40 antibodies
12/01/2005US20050265976 Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells
12/01/2005US20050265969 Therapeutic chemokine receptor antagonists
12/01/2005CA2567704A1 Selective serotonin receptor inverse agonists as therapeutics for disease
12/01/2005CA2567483A1 Pyrazinylmethyl lactam derivatives
12/01/2005CA2567343A1 N-cyclic sulfonamido inhibitors of gamma secretase
12/01/2005CA2566937A1 Substituted 2,5-diaminomethyl-1h-pyrroles
12/01/2005CA2566934A1 Tetrahydronaphthyl- piperazines as 5-ht1b antagonists, inverse agonists and partial agonists
12/01/2005CA2566923A1 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
12/01/2005CA2566090A1 Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
12/01/2005CA2565819A1 Methods of treating disease with random copolymers
12/01/2005CA2565029A1 Immediate release pharmaceutical tablets with height greater than width
12/01/2005CA2563968A1 Neurogenic pain control agent composition
12/01/2005CA2508585A1 Transdermal delivery system for treatment of cognitive disorders
11/2005
11/30/2005EP1600457A1 Peptide derivatives having beta-secretase inhibitory activity
11/30/2005EP1600440A1 Indole derivative compounds and drugs containing the compounds as the active ingredient
11/30/2005EP1600169A2 A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
11/30/2005EP1600168A2 A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
11/30/2005EP1600167A2 A pyrrolidineacetamide derivative alone in combination for treatment of CNS disorders
11/30/2005EP1600165A1 Medicinal use of mip-3alpha inhibitor and method of screening brain/nerve cell protective agent
11/30/2005EP1600163A1 Use of the neurotoxic component of botulinum toxins for the treatment of spastic muscle
11/30/2005EP1600160A1 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
11/30/2005EP1600156A2 Combination treatment for impaired motor function in parkinson's disease
11/30/2005EP1600154A1 Osmotic extended-release dosage form
11/30/2005EP1599479A1 Substituted imidazotriazines
11/30/2005EP1599476A1 Novel diazabicyclic aryl derivatives
11/30/2005EP1599475A2 Jnk inhibitors
11/30/2005EP1599464A2 Novel cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors
11/30/2005EP1599461A1 Thiolactones
11/30/2005EP1599231A2 Treatment of pain through expression of opioid receptors
11/30/2005EP1599220A1 Selection of patients with increased responsiveness to botulinum toxin
11/30/2005EP1599211A1 Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders
11/30/2005EP1599208A2 Antiglucocorticoids for the treatment of postpartum psychosis
11/30/2005EP1599205A1 Pten inhibitor or maxi-k channels opener
11/30/2005EP1599204A2 Selective mglu5 antagonists for treatment of neuromuscular dysfunction of the lower urinary tract
11/30/2005EP1599202A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
11/30/2005EP1599199A2 Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
11/30/2005EP1599197A2 The use of antimuscarinic drugs
11/30/2005EP1599167A2 Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament
11/30/2005EP1432708B1 Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity
11/30/2005EP1401839B9 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta [a] naphthalene
11/30/2005EP1289534B1 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
11/30/2005EP1246668B1 An rapid acting freeze dired oral pharmaceutical composition for treating migraine
11/30/2005EP1221941A4 Powder pharmaceutical formulations
1 ... 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 ... 1833